Clinical Trials · NCT00670501

Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

Name: Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

CompletedPhase 3Teriparatide

Phase: Phase 3
Recruitment status: Completed
Sponsor: Eli Lilly and Company
Enrollment: 1,637
Start date: Aug 1996
Locations: 17 sites, 17 countries
Primary endpoint: To demonstrate a reduction in the proportion of patients with new vertebral fractures (by spinal x-ray) following 3-year treatment with 20 and 40 micrograms/day of LY333334 plus calcium and vitamin D compared with calcium and vitamin D alone.

View Teriparatide compound reference